217 related articles for article (PubMed ID: 26710505)
1. Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia.
Ozaslan E; Eroglu E; Gok K; Senel S; Baldane S; Akyol L; Ozkan M
Rom J Intern Med; 2015; 53(3):282-5. PubMed ID: 26710505
[TBL] [Abstract][Full Text] [Related]
2. [Capecitabine-induced subacute cutaneous lupus: a case report].
Fongue J; Meunier B; Lardet D; Dicostanzo MP; Rouby F; Terrier JP; Harlé JR; Richard MA; Chiche L
Ann Dermatol Venereol; 2014 Oct; 141(10):593-7. PubMed ID: 25288062
[TBL] [Abstract][Full Text] [Related]
3. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
4. Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.
Shakhbazova A; Marsch AF
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045142
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
Wortmann S; Quinkler M; Ritter C; Kroiss M; Johanssen S; Hahner S; Allolio B; Fassnacht M
Eur J Endocrinol; 2010 Feb; 162(2):349-56. PubMed ID: 19903796
[TBL] [Abstract][Full Text] [Related]
6. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
7. A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer.
Fang W; Fu Y; Wei J
Curr Drug Saf; 2018; 13(1):55-58. PubMed ID: 28782476
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia.
Wiesenthal A; Matherne R; Gibson B
J Drugs Dermatol; 2012 Jun; 11(6):769-71. PubMed ID: 22648229
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Weger W; Kränke B; Gerger A; Salmhofer W; Aberer E
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S4-6. PubMed ID: 18625380
[TBL] [Abstract][Full Text] [Related]
10. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy.
Li Z; Jiang N; Xu Y
Australas J Dermatol; 2016 Feb; 57(1):e14-6. PubMed ID: 25495707
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Cetin B; Kaplan MA; Berk V; Tufan G; Benekli M; Isikdogan A; Ozkan M; Coskun U; Buyukberber S
Jpn J Clin Oncol; 2013 Jan; 43(1):28-32. PubMed ID: 23107836
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
[TBL] [Abstract][Full Text] [Related]
14. Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
Shaikh A; Wiisanen ME; Gunderson HD; Leung N
Ann Pharmacother; 2009 Jul; 43(7):1370-3. PubMed ID: 19584382
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine-induced myopericarditis - A case report and review of literature.
Saunders S; Anwar M
J Oncol Pharm Pract; 2019 Jun; 25(4):1006-1010. PubMed ID: 29783917
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced lupus erythematosus.
Vedove CD; Del Giglio M; Schena D; Girolomoni G
Arch Dermatol Res; 2009 Jan; 301(1):99-105. PubMed ID: 18797892
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced lupus erythematosus.
Sarzi-Puttini P; Atzeni F; Capsoni F; Lubrano E; Doria A
Autoimmunity; 2005 Nov; 38(7):507-18. PubMed ID: 16373256
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Vrdoljak E; Omrčen T; Boban M; Hrabar A
Anticancer Drugs; 2011 Feb; 22(2):191-7. PubMed ID: 21057306
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine-Related Thrombotic Microangiopathy.
Mateo FJP; Guasch AD; Pineda JAG; Manrique ACV; Cullell BM; López-Bravo DP; Díaz JG; Cascón AP; Freiria XB
J Gastrointest Cancer; 2024 Jun; 55(2):965-968. PubMed ID: 38175385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
